129 related articles for article (PubMed ID: 14629285)
1. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity.
Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
Am J Transplant; 2003 Dec; 3(12):1550-9. PubMed ID: 14629285
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.
Yang CW; Ahn HJ; Kim WY; Li C; Jung JY; Yoon SA; Kim YS; Cha JH; Kim J; Bang BK
Transplantation; 2003 Feb; 75(3):309-15. PubMed ID: 12589150
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity.
Yang CW; Ahn HJ; Kim WY; Li C; Kim HW; Choi BS; Cha JH; Kim YS; Kim J; Bang BK
Kidney Int; 2002 Jul; 62(1):20-30. PubMed ID: 12081560
[TBL] [Abstract][Full Text] [Related]
4. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity.
Shihab FS; Yi H; Bennett WM; Andoh TF
Kidney Int; 2000 Sep; 58(3):1174-85. PubMed ID: 10972680
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity.
Shihab FS; Bennett WM; Yi H; Andoh TF
Am J Transplant; 2002 Feb; 2(2):111-9. PubMed ID: 12099512
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.
Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
Kidney Int; 2004 Apr; 65(4):1262-71. PubMed ID: 15086465
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1.
Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
Transplantation; 2004 Mar; 77(5):683-6. PubMed ID: 15021829
[TBL] [Abstract][Full Text] [Related]
8. Sodium depletion enhances fibrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy.
Shihab FS; Andoh TF; Tanner AM; Bennett WM
Am J Kidney Dis; 1997 Jul; 30(1):71-81. PubMed ID: 9214404
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.
Shihab FS; Bennett WM; Tanner AM; Andoh TF
Kidney Int; 1997 Sep; 52(3):660-73. PubMed ID: 9291185
[TBL] [Abstract][Full Text] [Related]
10. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function.
Hueso M; Bover J; Serón D; Gil-Vernet S; Sabaté I; Fulladosa X; Ramos R; Coll O; Alsina J; Grinyó JM
Transplantation; 1998 Dec; 66(12):1727-31. PubMed ID: 9884267
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.
Feria I; Pichardo I; Juárez P; Ramírez V; González MA; Uribe N; García-Torres R; López-Casillas F; Gamba G; Bobadilla NA
Kidney Int; 2003 Jan; 63(1):43-52. PubMed ID: 12472767
[TBL] [Abstract][Full Text] [Related]
12. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction.
Islam M; Burke JF; McGowan TA; Zhu Y; Dunn SR; McCue P; Kanalas J; Sharma K
Kidney Int; 2001 Feb; 59(2):498-506. PubMed ID: 11168932
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone limits cyclosporine nephrotoxicity in rats.
Pereira MG; Câmara NO; Campaholle G; Cenedeze MA; de Paula Antunes Teixeira V; dos Reis MA; Pacheco-Silva A
Int Immunopharmacol; 2006 Dec; 6(13-14):1943-51. PubMed ID: 17161347
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal study of TGF-beta1 protein levels in renal allograft recipients converted from CsA to MMF or AZA.
van der Mast BJ; van Besouw NM; de Kuiper P; Vaessen LM; IJzermans JN; van Gelder T; Weimar W
Clin Transplant; 2000 Feb; 14(1):66-9. PubMed ID: 10693638
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity.
Shihab FS; Bennett WM; Tanner AM; Andoh TF
Transplantation; 1997 Dec; 64(12):1829-37. PubMed ID: 9422427
[TBL] [Abstract][Full Text] [Related]
17. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy.
Shihab FS; Andoh TF; Tanner AM; Noble NA; Border WA; Franceschini N; Bennett WM
Kidney Int; 1996 Apr; 49(4):1141-51. PubMed ID: 8691736
[TBL] [Abstract][Full Text] [Related]
18. Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts.
Shimizu H; Takahashi M; Takeda S; Inoue S; Fujishiro J; Hakamata Y; Kaneko T; Murakami T; Takeyoshi I; Morishita Y; Kobayashi E
Transpl Immunol; 2004 Nov; 13(3):219-27. PubMed ID: 15381205
[TBL] [Abstract][Full Text] [Related]
19. Expression of transforming growth factor-beta-inducible gene-h3 in normal and cyclosporine-treated rat kidney.
Sun BK; Li C; Lim SW; Jung JY; Lee SH; Kim IS; Kim YS; Kim J; Bang BK; Yang CW
J Lab Clin Med; 2004 Mar; 143(3):175-83. PubMed ID: 15007308
[TBL] [Abstract][Full Text] [Related]
20. Blockade of angiotensin II with losartan attenuates transforming growth factor-beta1 inducible gene-h3 (betaig-h3) expression in a model of chronic cyclosporine nephrotoxicity.
Sun BK; Li C; Lim SW; Choi BS; Lee SH; Kim IS; Kim YS; Bang BK; Yang CW
Nephron Exp Nephrol; 2005; 99(1):e9-16. PubMed ID: 15637465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
